Brokerages Set argenex SE (NASDAQ:ARGX) Target Price at $1,037.61

argenex SE (NASDAQ:ARGX) has earned a consensus rating of “Moderate Buy” from the twenty-four research firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $1,042.6667.

A number of research firms have recently commented on ARGX. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Thursday, June 11th. Glj Research upgraded argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Royal Bank Of Canada increased their target price on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Oppenheimer cut their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Finally, Bank of America lifted their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd.

Institutional Investors Weigh In On argenex

Institutional investors have recently added to or reduced their stakes in the stock. Merit Financial Group LLC boosted its stake in argenex by 17.1% in the 2nd quarter. Merit Financial Group LLC now owns 466 shares of the company’s stock worth $432,000 after purchasing an additional 68 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of argenex by 9.6% in the second quarter. Farther Finance Advisors LLC now owns 365 shares of the company’s stock valued at $338,000 after purchasing an additional 32 shares in the last quarter. Ballentine Partners LLC lifted its holdings in shares of argenex by 30.8% in the second quarter. Ballentine Partners LLC now owns 772 shares of the company’s stock valued at $716,000 after purchasing an additional 182 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in shares of argenex during the second quarter worth about $27,584,000. Finally, Sequoia Financial Advisors LLC boosted its position in shares of argenex by 4.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,045 shares of the company’s stock worth $1,897,000 after buying an additional 84 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex Stock Up 8.6%

Shares of ARGX stock opened at $924.60 on Tuesday. argenex has a 12-month low of $577.04 and a 12-month high of $953.58. The firm has a fifty day moving average of $865.90 and a 200-day moving average of $814.39. The firm has a market capitalization of $57.84 billion, a price-to-earnings ratio of 41.17, a price-to-earnings-growth ratio of 1.05 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 44.37% and a net margin of 31.31%. Research analysts expect that argenex will post 26.27 earnings per share for the current year.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported Q2 2026 EPS of $7.32, ahead of consensus at $5.86, and revenue of $1.54 billion versus expectations of $1.45 billion, reinforcing the view that execution remains strong. argenx earnings report and conference call
• Positive Sentiment: Global Vyvgart sales jumped sharply in the second quarter, with one report citing about 60% growth year over year, signaling accelerating demand for argenx’s lead product. Reuters article on Vyvgart sales jump
• Positive Sentiment: The company’s half-year 2026 results and business update point to continued commercial progress and a supportive backdrop as additional pipeline readouts approach. Half-year 2026 financial results and business update
• Positive Sentiment: Guggenheim reiterated a Buy rating, adding to the bullish sentiment around the stock after the earnings release. Guggenheim Buy rating article
• Neutral Sentiment: Investors are also focusing on the Q2 earnings call transcript and related coverage for more detail on management’s outlook, pipeline timing, and launch execution. Q2 2026 earnings call transcript

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.